BioSpace2h
Emalex Heads to FDA After Phase III Tourette Syndrome Win
In the Phase III trial, 41.9% of pediatric Tourette syndrome patients relapsed after ecopipam treatment, as compared with ...
FierceBiotech23h
Emalex dopamine blocker stops Tourette syndrome relapse in phase 3 win
Emalex Biosciences’ dopamine blocker led to fewer patients with Tourette syndrome relapsing in a phase 3 trial, setting the ...
MedPage Today1h
'Banned' Words at CDC? House Passes Budget Bill; Measles Outbreak in Texas Expands
CDC staff received an email this week telling them to avoid using more than a dozen terms or words -- including "health ...
ENDPOINTS NEWS20h
Chica­go biotech Emalex says it cleared a Phase 3 for Tourette syn­drome, will seek FDA ap­proval
Emalex Biosciences said its daily oral tablet helped reduce relapses for children and adults with Tourette syndrome in a ...
The Pharma Letter1h
Ligand invests $75 million in Castle Creek’s gene therapy
Ligand Pharmaceuticals (Nasdaq: LGND) has entered into a royalty financing agreement with Castle Creek Biosciences, providing ...